|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DPYSL3 |
Gene summary for DPYSL3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DPYSL3 | Gene ID | 1809 |
| Gene name | dihydropyrimidinase like 3 | |
| Gene Alias | CRMP-4 | |
| Cytomap | 5q32 | |
| Gene Type | protein-coding | GO ID | GO:0006928 | UniProtAcc | A0A140VK07 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1809 | DPYSL3 | LZE4T | Human | Esophagus | ESCC | 5.03e-06 | 2.24e-01 | 0.0811 |
| 1809 | DPYSL3 | LZE7T | Human | Esophagus | ESCC | 1.86e-09 | 8.30e-01 | 0.0667 |
| 1809 | DPYSL3 | LZE8T | Human | Esophagus | ESCC | 7.46e-10 | 4.58e-01 | 0.067 |
| 1809 | DPYSL3 | LZE24T | Human | Esophagus | ESCC | 1.26e-04 | 2.01e-01 | 0.0596 |
| 1809 | DPYSL3 | LZE21T | Human | Esophagus | ESCC | 1.68e-05 | 5.91e-01 | 0.0655 |
| 1809 | DPYSL3 | P2T-E | Human | Esophagus | ESCC | 1.74e-05 | 2.81e-01 | 0.1177 |
| 1809 | DPYSL3 | P4T-E | Human | Esophagus | ESCC | 1.16e-15 | 6.17e-01 | 0.1323 |
| 1809 | DPYSL3 | P5T-E | Human | Esophagus | ESCC | 1.57e-22 | 4.78e-01 | 0.1327 |
| 1809 | DPYSL3 | P8T-E | Human | Esophagus | ESCC | 5.85e-35 | 6.64e-01 | 0.0889 |
| 1809 | DPYSL3 | P9T-E | Human | Esophagus | ESCC | 1.01e-33 | 8.43e-01 | 0.1131 |
| 1809 | DPYSL3 | P10T-E | Human | Esophagus | ESCC | 5.33e-21 | 4.92e-01 | 0.116 |
| 1809 | DPYSL3 | P11T-E | Human | Esophagus | ESCC | 2.81e-28 | 1.21e+00 | 0.1426 |
| 1809 | DPYSL3 | P12T-E | Human | Esophagus | ESCC | 1.80e-43 | 1.05e+00 | 0.1122 |
| 1809 | DPYSL3 | P15T-E | Human | Esophagus | ESCC | 8.89e-34 | 9.03e-01 | 0.1149 |
| 1809 | DPYSL3 | P16T-E | Human | Esophagus | ESCC | 6.79e-12 | 5.16e-02 | 0.1153 |
| 1809 | DPYSL3 | P19T-E | Human | Esophagus | ESCC | 1.63e-13 | 1.26e+00 | 0.1662 |
| 1809 | DPYSL3 | P21T-E | Human | Esophagus | ESCC | 1.58e-35 | 7.25e-01 | 0.1617 |
| 1809 | DPYSL3 | P22T-E | Human | Esophagus | ESCC | 1.35e-02 | 1.42e-01 | 0.1236 |
| 1809 | DPYSL3 | P23T-E | Human | Esophagus | ESCC | 2.95e-43 | 1.19e+00 | 0.108 |
| 1809 | DPYSL3 | P24T-E | Human | Esophagus | ESCC | 1.32e-09 | 4.26e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
| GO:005101727 | Esophagus | ESCC | actin filament bundle assembly | 100/8552 | 157/18723 | 3.87e-06 | 4.17e-05 | 100 |
| GO:006157227 | Esophagus | ESCC | actin filament bundle organization | 101/8552 | 161/18723 | 9.22e-06 | 8.82e-05 | 101 |
| GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
| GO:001097516 | Esophagus | ESCC | regulation of neuron projection development | 240/8552 | 445/18723 | 2.48e-04 | 1.53e-03 | 240 |
| GO:006049118 | Esophagus | ESCC | regulation of cell projection assembly | 110/8552 | 188/18723 | 2.60e-04 | 1.58e-03 | 110 |
| GO:012003218 | Esophagus | ESCC | regulation of plasma membrane bounded cell projection assembly | 108/8552 | 186/18723 | 4.37e-04 | 2.46e-03 | 108 |
| GO:01200347 | Esophagus | ESCC | positive regulation of plasma membrane bounded cell projection assembly | 64/8552 | 105/18723 | 1.15e-03 | 5.70e-03 | 64 |
| GO:00486785 | Esophagus | ESCC | response to axon injury | 51/8552 | 83/18723 | 2.74e-03 | 1.16e-02 | 51 |
| GO:00109764 | Esophagus | ESCC | positive regulation of neuron projection development | 91/8552 | 163/18723 | 5.72e-03 | 2.13e-02 | 91 |
| GO:00070158 | Lung | IAC | actin filament organization | 92/2061 | 442/18723 | 1.01e-09 | 1.93e-07 | 92 |
| GO:00510178 | Lung | IAC | actin filament bundle assembly | 40/2061 | 157/18723 | 2.66e-07 | 2.14e-05 | 40 |
| GO:00615728 | Lung | IAC | actin filament bundle organization | 40/2061 | 161/18723 | 5.43e-07 | 3.32e-05 | 40 |
| GO:00109756 | Lung | IAC | regulation of neuron projection development | 82/2061 | 445/18723 | 1.82e-06 | 8.78e-05 | 82 |
| GO:00313455 | Lung | IAC | negative regulation of cell projection organization | 41/2061 | 186/18723 | 1.01e-05 | 3.23e-04 | 41 |
| GO:01200327 | Lung | IAC | regulation of plasma membrane bounded cell projection assembly | 39/2061 | 186/18723 | 5.41e-05 | 1.21e-03 | 39 |
| GO:00604916 | Lung | IAC | regulation of cell projection assembly | 39/2061 | 188/18723 | 6.92e-05 | 1.47e-03 | 39 |
| GO:00313466 | Lung | IAC | positive regulation of cell projection organization | 63/2061 | 353/18723 | 7.37e-05 | 1.55e-03 | 63 |
| GO:00109774 | Lung | IAC | negative regulation of neuron projection development | 27/2061 | 137/18723 | 1.88e-03 | 1.92e-02 | 27 |
| GO:2000146 | Lung | IAC | negative regulation of cell motility | 56/2061 | 359/18723 | 4.58e-03 | 3.62e-02 | 56 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DPYSL3 | SNV | Missense_Mutation | c.1470N>A | p.Asp490Glu | p.D490E | Q14195 | protein_coding | deleterious(0) | possibly_damaging(0.815) | TCGA-A8-A076-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| DPYSL3 | SNV | Missense_Mutation | rs750296589 | c.545N>A | p.Gly182Glu | p.G182E | Q14195 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| DPYSL3 | SNV | Missense_Mutation | c.760N>C | p.Asp254His | p.D254H | Q14195 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-BH-A0B7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
| DPYSL3 | SNV | Missense_Mutation | rs754356799 | c.1471N>A | p.Glu491Lys | p.E491K | Q14195 | protein_coding | deleterious(0.01) | probably_damaging(0.977) | TCGA-BH-A5J0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DPYSL3 | SNV | Missense_Mutation | c.1423N>T | p.Arg475Trp | p.R475W | Q14195 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DPYSL3 | SNV | Missense_Mutation | c.1036N>A | p.Glu346Lys | p.E346K | Q14195 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-E9-A1NA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| DPYSL3 | SNV | Missense_Mutation | c.424N>A | p.Asp142Asn | p.D142N | Q14195 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-GM-A2DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| DPYSL3 | SNV | Missense_Mutation | rs757343684 | c.1570G>A | p.Val524Ile | p.V524I | Q14195 | protein_coding | deleterious(0.04) | benign(0.212) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DPYSL3 | SNV | Missense_Mutation | c.732G>C | p.Lys244Asn | p.K244N | Q14195 | protein_coding | deleterious(0.01) | probably_damaging(0.934) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| DPYSL3 | SNV | Missense_Mutation | rs751361322 | c.1900C>T | p.Arg634Trp | p.R634W | Q14195 | protein_coding | deleterious(0) | possibly_damaging(0.821) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1809 | DPYSL3 | NA | METHIMAZOLE | METHIMAZOLE | 11694350 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |